Dysbetalipoproteinemia Is Associated With Increased Risk of Coronary and Peripheral Vascular Disease

J Clin Endocrinol Metab. 2022 Dec 17;108(1):184-190. doi: 10.1210/clinem/dgac503.

Abstract

Context: Dysbetalipoproteinemia (DBL) is a disorder in which remnant lipoproteins accumulate in the plasma due to a genetic apolipoprotein E dysfunction in conjunction with the presence of secondary metabolic factors. An increased risk of both coronary and peripheral vascular disease (PVD) has been observed in these patients in retrospective studies.

Objective: The primary objective was to compare the incidence of atherosclerotic cardiovascular disease (ASCVD) and PVD in a cohort of patients with DBL compared with normolipidemic controls. As a secondary objective, the incidence of ASCVD and PVD was compared between patients with DBL and patients with familial hypercholesterolemia (FH).

Methods: A total of 221 patients with DBL, 725 patients with FH, and 1481 normolipidemic controls were included in the study. The data were obtained by review of medical records.

Results: In patients with DBL, there was an overall excess risk of PVD (hazard ratio [HR] 13.58, 95% CI 4.76-38.75) and ASCVD (HR 3.55, 95% CI 2.17-5.83) (P < .0001) when compared with normolipidemic controls. When compared with patients with FH, an increased risk of PVD (HR 3.89, 95% CI 1.20-12.55, P = .02) was observed in patients with DBL.

Conclusion: We demonstrated that the risks of ASCVD and PVD in DBL are >3-fold and >13-fold higher, respectively, than normolipidemic controls. Furthermore, the risk of PVD is ∼4-fold higher in DBL than in FH. Adequate screening of DBL is imperative to improve the clinical care of these patients by preventing the development of ASCVD.

Keywords: cardiovascular disease; dysbetalipoproteinemia; dyslipidemia; familial hypercholesterolemia; peripheral vascular disease; remnant.

MeSH terms

  • Humans
  • Hyperlipoproteinemia Type II* / complications
  • Hyperlipoproteinemia Type II* / epidemiology
  • Hyperlipoproteinemia Type III* / complications
  • Incidence
  • Peripheral Vascular Diseases* / complications
  • Retrospective Studies
  • Risk Factors